3 active not recruiting, 1 enrolling by invitation. 2 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 2 |
| Phase 3 | 2 | Active not recruiting 1, Enrolling by invitation 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow ONC-392: new trials by email Literature Review of ONC-392 trials Research Report on ONC-392
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gotistobart Long Term Extension (LTE) Study Gotistobart - Advanced Solid Tumor | Phase 3 | Enrolling by invitation | OncoC4, Inc. | 20 | 2026-07-28 | 2026-08-24 |
| ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors Gotistobart, Docetaxel - Non Small Cell Lung Cancer | Phase 3 | Active not recruiting | OncoC4, Inc. | 630 | 2023-06-28 | 2026-08-13 |
| ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer ONC-392, Pembrolizumab - Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary | Phase 2 | Active not recruiting | OncoC4, Inc. | 58 | 2022-12-22 | 2026-09-22 |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC ONC-392, Pembrolizumab, Docetaxel - Non Small Cell Lung Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | OncoC4, Inc. | 733 | 2020-09-16 | 2026-09-14 |
Carcinoma, Non-Small-Cell Lung (2) · Ovarian Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Melanoma (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Salivary Gland Neoplasms (1) · Sarcoma (1) · Small Cell Lung Carcinoma (1)
OncoC4, Inc. (4)
United States (4) · Australia (2) · Belgium (1) · Canada (1) · China (1) · Germany (1) · Italy (1) · Netherlands (1) · South Korea (1) · Spain (1) · Turkey (Türkiye) (1) · United Kingdom (1)
Bradley Monk, MD (1) · Joyce Barlin, MD (1) · Kai He, MD, PhD (1) · Mark Socinski, MD (1) · Tianhong Li, MD (1) · Tianhong Li, MD, PhD (1)
2023 (1), R44CA250824 (1)